Use of Ibandronate in Diabetic Patients

Completed 121 enrolled Yeouido St. Mary's Hospital Samsung Medical Center · collab Seoul National University Bundang Hospital · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patients without diabetes.

Timeline

Start: 2018-10-01
Primary completion: 2021-08-30
Completion: 2022-01-31

Publications

Kim J, Kim KM, Lim S, Kang MI, Baek KH, Min YK. Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial. BMC Endocr Disord. 2022 Apr 11;22(1):99. doi: 10.1186/s12902-022-01010-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ibandronate	Other / unclassified	150 mg	Oral
Background	Cholecalciferol	Other / unclassified	24000 iu	Oral

Use of Ibandronate in Diabetic Patients

Summary

Timeline

Publications

Drugs

Indications